

## **Access to medicines outside of public funding Roche Products New Zealand (RPNZ) Policy**

### **Position Summary**

- RPNZ's aim is for every person who needs our medicines to be able to benefit from them.
- The New Zealand government has primary responsibility for New Zealand's universal healthcare system, which provides funded access to many medicines via PHARMAC and public hospitals.
- RPNZ acknowledges that the absence of public funding for a prescribed medicine may represent a significant financial burden and difficult choice for patients.
- In situations where there is no public funding, RPNZ may be able to assist patients with alternative pathways to access medicines, such as private purchase via cost share programmes.

### **RPNZ position**

Access to quality healthcare is a shared responsibility, requiring all stakeholders to work together. At RPNZ, we believe our primary contribution is to innovate healthcare by:

- Delivering diagnostics to support early detection, accurate diagnosis and individualised care
- Delivering medicines that significantly improve people's lives.

Our aim is for every person who needs our medicines to be able to access them and receive full therapeutic benefit.

RPNZ believes that the most effective, safe, equitable and sustainable means of access to medicines is via established regulatory and reimbursement pathways, Medsafe NZ and PHARMAC. The government has primary responsibility for New Zealand's universal healthcare system, which provides funded access to many medicines via PHARMAC.

RPNZ recognises that patients sometimes need access to medicines outside of the established access pathways, such as for life-threatening diseases with limited licenced options or licenced medicines not publicly funded. We recognise that the absence of public funding for a prescribed medicine may represent a significant financial burden and difficult choice for many patients and their families.

In situations where there is no public funding, RPNZ may be able to assist patients with alternative pathways to access to medicines, such as private purchase via cost share programmes.

*All requests for access in these circumstances must come to RPNZ via a patient's treating healthcare professional.*

### **Further reference**

Roche Global Position on Pre-Approval Access to Investigational Medicinal Products (Global policy): [link](#).

Roche Products (New Zealand) Limited  
98 Carlton Gore Road Newmarket  
Auckland 1023  
PO Box 109113  
Newmarket, Auckland 1149 New Zealand  
Phone +64 9 523 9400 Fax +64 9 523  
9465 Toll Free 0800 656 464